Concord, CA
Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.
cerus.comThese are collections Cerus is a part of. Click on the collection name to view similar companies.
Post Ipo Equity
$63,300,000
Grant
$15,000,000
Post Ipo Equity
$57,500,000
Post Ipo Equity
$70,000,000
Post Ipo Debt
$30,000,000
IPO
Unknown
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Cerus.